The trend towards personalized medicine is omnipresent: more and more innovative drugs depend on an upfront diagnosis of biomarkers to ensure safe and effective therapy. The search for viable markers thus increasingly becomes an integral part of modern drug development.
Thanks to our pharmaceutical experts within regenold GmbH we are optimally prepared to support the (co-)development of Companion Diagnostics (CDx) both for developers of diagnostics as well as pharmaceutical companies. Having access to a vast network of partners and clients enables us to also help you identifying potential partners for the development of your CDx.
We are very proud to have supported our clients in successfully CE marking their Companion Diagnostics.